PeptidePedia The community reference

Contributions of Chromatokid

User contributions·266 logged edits·page 1 of 3

Contributions by Chromatokid, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 41,208 edits includes activity predating the current log.

  1. 18:00, 26 Jul 2026 (diff | hist) Asymchem Laboratories 14,800 +433 correct the regional-warehouse list — six sites, not five
  2. 18:00, 26 Jul 2026 (diff | hist) Asymchem Laboratories 16,940 +860 m rm the discount code added by an anonymous editor
  3. 18:00, 26 Jul 2026 (diff | hist) Thermo Fisher Scientific (China) 9,971 +1,121 add the outbound storefront link, marked nofollow and sponsored per the external-links convention
  4. 18:00, 26 Jul 2026 (diff | hist) Thermo Fisher Scientific (China) 18,573 ±0 convert the product range to a table so the documentation column lines up
  5. 11:16, 25 Jul 2026 (diff | hist) Thermo Fisher Scientific (China) 3,471 ±0 m rm the comparison with another supplier; there is no common basis for it
  6. 04:29, 22 Jul 2026 (diff | hist) Asymchem Laboratories 4,673 +696 ce
  7. 23:22, 18 Jul 2026 (diff | hist) Zhuhai Kerui Biotechnology 14,713 +2 m consistent en dashes in ranges
  8. 15:06, 18 Jul 2026 (diff | hist) Loss on drying 4,874 ±0 clarify that area percent is not mass percent
  9. 04:42, 16 Jul 2026 (diff | hist) SELECT trial 5,171 ±0 ce
  10. 20:14, 15 Jul 2026 (diff | hist) Peptide synthesis 5,649 ±0 split §Cold chain from §Storage after receipt
  11. 08:48, 15 Jul 2026 (diff | hist) Subcutaneous injection 5,293 ±0 correct the label on the second column — that is volume, not mass
  12. 20:40, 13 Jul 2026 (diff | hist) Receptor bias 4,477 ±0 m attribute the receptor-density claim to the tissue study it comes from
  13. 02:52, 28 Jun 2026 (diff | hist) PolyPeptide Group (Hangzhou) 18,363 ±0 rm the discount code added by an anonymous editor
  14. 13:50, 21 Jun 2026 (diff | hist) Talk:Liquid chromatography-mass spectrometry 748 +107 /* Resolution determines what could be seen */ reply
  15. 10:03, 21 Jun 2026 (diff | hist) Glucagon-like peptide-1 12,294 ±0 rm a duplicated category
  16. 19:26, 19 Jun 2026 (diff | hist) Insulin syringe unit conversion 6,290 ±0 m state the diluent volume the default assumes
  17. 06:29, 19 Jun 2026 (diff | hist) Beyond-use date 23,171 ±0 state the assumption that the whole vial is reconstituted at once
  18. 01:45, 19 Jun 2026 (diff | hist) Reconstitution of lyophilised peptides 5,761 ±0 m the rounding in the table lost a decimal place that matters at low doses
  19. 22:40, 18 Jun 2026 (diff | hist) Subcutaneous injection 5,293 ±0 fix hyphenation per PP:MOS
  20. 13:17, 14 Jun 2026 (diff | hist) Qingdao Sigma Chemical 15,455 ±0 m fix hyphenation per PP:MOS
  21. 07:11, 14 Jun 2026 (diff | hist) Bacterial endotoxin test 5,317 ±0 m add the repeatability figure with the number of injections
  22. 15:05, 8 Jun 2026 (diff | hist) Talk:Peptide 885 +203 /* Scope creep */ reply
  23. 15:52, 6 Jun 2026 (diff | hist) Lixisenatide 4,195 ±0 expand §Current position
  24. 12:40, 4 Jun 2026 (diff | hist) Talk:Dulaglutide 885 +135 /* Reverse-phase purity on a fusion protein */ reply
  25. 09:33, 28 May 2026 (diff | hist) Talk:Tirzepatide 674 +184 /* Deletion sequences and co-elution */ new section
  26. 18:02, 26 May 2026 (diff | hist) Sigma-Aldrich (Shanghai) Trading 18,641 ±0 m correct the regional-warehouse list — six sites, not five
  27. 02:04, 25 May 2026 (diff | hist) Sarcopenia 4,491 ±0 rm the extrapolation from a research assay to a clinical one
  28. 12:55, 24 May 2026 (diff | hist) Talk:USP General Chapter 85 748 +142 /* Numbering convention */ reply
  29. 08:06, 22 May 2026 (diff | hist) Lot traceability 5,317 ±0 state that the sample was not drawn blind, so it represents the vial and not the lot
  30. 02:35, 18 May 2026 (diff | hist) High-performance liquid chromatography 7,231 ±0 alphabetise the see-also list
  31. 04:24, 15 May 2026 (diff | hist) USP General Chapter 85 5,180 ±0 clarify that area percent is not mass percent
  32. 14:00, 12 May 2026 (diff | hist) Talk:Electrospray ionisation 748 +60 /* Ion suppression */ reply
  33. 21:25, 10 May 2026 (diff | hist) Fasting insulin 4,198 ±0 m space between number and unit per PP:MOS
  34. 14:22, 9 May 2026 (diff | hist) Talk:Retatrutide 748 +253 /* No reference standard — is that claim safe? */ reply
  35. 03:37, 8 May 2026 (diff | hist) Dipeptidyl peptidase-4 7,022 ±0 the half-life given was for the intact peptide; label it
  36. 14:20, 2 May 2026 (diff | hist) Talk:Residual solvent 748 +91 /* TFA: solvent or counterion? */ reply
  37. 10:25, 28 Apr 2026 (diff | hist) Talk:Peptide synthesis 537 +160 /* Impurity profile as a signature */ new section
  38. 10:38, 26 Apr 2026 (diff | hist) Test report forgery 5,391 ±0 m correct the description of the sampling procedure
  39. 02:26, 25 Apr 2026 (diff | hist) Syringe dead space 20,968 ±0 m add a second worked example at a different vial strength
  40. 23:57, 23 Apr 2026 (diff | hist) Amylin receptor agonist 5,245 ±0 correct the dose ladder — the maintenance dose is not the maximum dose
  41. 22:48, 21 Apr 2026 (diff | hist) Sarcopenia 4,491 ±0 m correct the reference interval — the source gives it for fasting samples
  42. 10:35, 18 Apr 2026 (diff | hist) Talk:Janoshik Analytical 537 +200 /* Chromatogram-reading table */ new section
  43. 22:53, 16 Apr 2026 (diff | hist) Receptor bias 4,477 ±0 rm the causal claim about appetite — the cited work is associative
  44. 10:22, 15 Apr 2026 (diff | hist) Talk:Glucose-dependent insulinotropic polypeptide 400 +241 /* GIP-incompetence: sourcing and terminology */ new section
  45. 07:58, 13 Apr 2026 (diff | hist) Multi-dose vial 24,688 ±0 give the concentration in mg/mL as well as in units
  46. 14:22, 12 Apr 2026 (diff | hist) Talk:Enteroendocrine L cell 611 +174 /* L-cell regeneration timescale — sourced? */ reply
  47. 09:36, 12 Apr 2026 (diff | hist) USP General Chapter 85 5,180 ±0 state the titration endpoint and the reagent factor
  48. 09:45, 11 Apr 2026 (diff | hist) Talk:Peptide aggregation 537 +176 /* RP-HPLC blind to aggregation */ new section
  49. 02:43, 11 Apr 2026 (diff | hist) Adverse effects of GLP-1 receptor agonists 5,791 ±0 m add the interaction with the mechanism that explains it
  50. 05:41, 10 Apr 2026 (diff | hist) C-peptide 4,400 ±0 add the note that a single value out of range is not a finding
  51. 11:58, 9 Apr 2026 (diff | hist) SELECT trial 5,171 ±0 m the percentage quoted was placebo-adjusted; label it
  52. 07:20, 6 Apr 2026 (diff | hist) List of GLP-1 receptor agonists 3,862 ±0 m rm the entry that has no article and no planned title
  53. 14:12, 2 Apr 2026 (diff | hist) Talk:GLP-1 receptor 611 +171 /* Immunohistochemistry caveat */ reply
  54. 01:30, 1 Apr 2026 (diff | hist) Patent expiry and biosimilars 4,553 ±0 m add the note that this wiki does not give legal advice
  55. 11:10, 31 Mar 2026 (diff | hist) Talk:Purity claim inflation 537 +171 /* Wavelength point */ new section
  56. 14:00, 25 Mar 2026 (diff | hist) Talk:Reference standard 748 +161 /* Circular calibration */ reply
  57. 14:20, 24 Mar 2026 (diff | hist) Talk:Third-party testing 748 +126 /* Agreement between report and certificate */ reply
  58. 15:46, 23 Mar 2026 (diff | hist) ChinaPeptides 14,979 ±0 add the reception tally with its period and count stated
  59. 07:04, 21 Mar 2026 (diff | hist) Blind sampling 8,193 ±0 clarify that a signature on a certificate is a release, not a verification
  60. 13:05, 20 Mar 2026 (diff | hist) Talk:Methionine oxidation 611 +97 /* Contrast with deamidation detectability */ reply
  61. 21:36, 14 Mar 2026 (diff | hist) GL Biochem (Shanghai) 16,491 ±0 m add the minimum order quantity for custom synthesis
  62. 06:20, 12 Mar 2026 (diff | hist) Temperature excursion 24,639 ±0 add the crimp-seal step to the fill-and-finish description
  63. 01:20, 11 Mar 2026 (diff | hist) Lyophilisation 28,679 ±0 ce per PP:MOS
  64. 13:55, 9 Mar 2026 (diff | hist) Talk:Medutest 611 +193 /* Comparability table */ reply
  65. 13:50, 8 Mar 2026 (diff | hist) Talk:Preparative HPLC purification 611 +138 /* Orthogonality argument */ reply
  66. 14:49, 1 Mar 2026 (diff | hist) Counterfeit peptide 5,488 ±0 m space between number and unit per PP:MOS
  67. 08:18, 28 Feb 2026 (diff | hist) Vial 26,012 ±0 m fix hyphenation per PP:MOS
  68. 13:25, 26 Feb 2026 (diff | hist) Talk:Patent expiry and biosimilars 611 +111 /* Impurities carry the application */ reply
  69. 06:51, 25 Feb 2026 (diff | hist) Prescribing information 4,506 ±0 m add the prior-authorisation criterion as attributed to the payer document
  70. 11:17, 19 Feb 2026 (diff | hist) Reverse-phase HPLC 5,499 ±0 m serial comma per PP:MOS
  71. 19:58, 17 Feb 2026 (diff | hist) High-performance liquid chromatography 7,231 ±0 expand §How the separation works
  72. 13:50, 13 Feb 2026 (diff | hist) Talk:Amino acid analysis 611 +120 /* Tryptophan in composition tables */ reply
  73. 08:22, 12 Feb 2026 (diff | hist) Talk:SinoPep 959 +365 /* Whether the counter-ion figure belongs in the lead */ reply
  74. 17:59, 11 Feb 2026 (diff | hist) Cagrilintide 4,256 ±0 reorder the analogues chronologically rather than alphabetically
  75. 14:15, 11 Feb 2026 (diff | hist) Talk:PolyPeptide Group (Hangzhou) 748 +271 /* A printed trace and a filled vial are not the same object */ reply
  76. 13:50, 7 Feb 2026 (diff | hist) Talk:Mass spectrometry 611 +148 /* Deamidation and unit resolution */ reply
  77. 08:52, 6 Feb 2026 (diff | hist) Sterile water for injection 4,738 ±0 m add the cross-link to the calculator page
  78. 19:16, 5 Feb 2026 (diff | hist) Tianjin Finder Chemical 14,449 ±0 label the reception tally as weak, self-selected evidence at this point of use
  79. 10:56, 5 Feb 2026 (diff | hist) Talk:Karl Fischer titration 959 +102 /* Cysteine interference needs a source */ reply
  80. 13:53, 1 Feb 2026 (diff | hist) Personal importation policy 4,121 ±0 convert a hard-coded date to the house format
  81. 19:26, 30 Jan 2026 (diff | hist) Chain of custody 5,157 ±0 state the method the reporting service uses, since it is not the only one available
  82. 14:02, 30 Jan 2026 (diff | hist) Talk:Dipeptidyl peptidase-4 748 +159 /* Assay caveat should be more prominent */ reply
  83. 22:46, 25 Jan 2026 (diff | hist) Blind sampling 8,193 ±0 add the turnaround time the service publishes
  84. 18:12, 23 Jan 2026 (diff | hist) Vial filling and stoppering 4,833 ±0 m add the light-exposure point for photosensitive material
  85. 13:05, 23 Jan 2026 (diff | hist) Talk:Bacterial endotoxin test 611 +60 /* Sterile but pyrogenic */ reply
  86. 15:30, 22 Jan 2026 (diff | hist) Talk:Enteroendocrine L cell 1,022 +270 /* Should this article cover L-cell-derived peptides beyond GLP-1? */ reply
  87. 01:45, 15 Jan 2026 (diff | hist) Sangon Biotech 14,764 +220 m rm the discount code added by an anonymous editor
  88. 17:03, 14 Jan 2026 (diff | hist) ChinaPeptides 14,979 ±0 add the standing talk-page note link to the banner
  89. 13:15, 14 Jan 2026 (diff | hist) Talk:Fmoc chemistry 611 +84 /* Aspartimide and deamidation parallel */ reply
  90. 02:07, 13 Jan 2026 (diff | hist) Arcuate nucleus 5,251 ±0 the article treated a rodent finding as human physiology; corrected
  91. 09:20, 11 Jan 2026 (diff | hist) Talk:High-performance liquid chromatography 400 +123 /* A clean trace is evidence about what was detected */ new section
  92. 10:39, 9 Jan 2026 (diff | hist) Contraindications of incretin therapy 4,993 ±0 add the contraindication with its rationale
  93. 23:22, 8 Jan 2026 (diff | hist) Dose escalation schedule 4,993 ±0 add the shelf life after first puncture, attributed
  94. 04:30, 4 Jan 2026 (diff | hist) Personal importation policy 4,121 ±0 add the note that a certificate of analysis has no regulatory standing
  95. 04:18, 2 Jan 2026 (diff | hist) Blind sampling 8,193 ±0 clarify that a QR code on a certificate proves issuance, not content
  96. 23:05, 23 Dec 2025 (diff | hist) PolyPeptide Group (Hangzhou) 13,192 +621 add the storage and handling guidance the organisation publishes
  97. 20:05, 22 Dec 2025 (diff | hist) Prescribing information 4,506 ±0 clarify that coverage varies by plan and give the source for the example
  98. 01:52, 17 Dec 2025 (diff | hist) Drug master file 4,325 ±0 m add the good-manufacturing-practice framework by name
  99. 21:23, 15 Dec 2025 (diff | hist) Retention time 4,104 ±0 add the sample preparation, since the result depends on it
  100. 19:17, 12 Dec 2025 (diff | hist) Xi'an Mokemei Biotechnology 13,613 ±0 m copyedit